Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

A phase III trial of tirasemtiv as a potential treatment for amyotrophic lateral sclerosis.

Shefner JM, Cudkowicz ME, Hardiman O, Cockroft BM, Lee JH, Malik FI, Meng L, Rudnicki SA, Wolff AA, Andrews JA; VITALITY-ALS STUDY GROUP.

Amyotroph Lateral Scler Frontotemporal Degener. 2019 May 13:1-11. doi: 10.1080/21678421.2019.1612922. [Epub ahead of print] Erratum in: Amyotroph Lateral Scler Frontotemporal Degener. 2019 Jul 14;:1.

PMID:
31081694
2.

Understanding the use of NIV in ALS: results of an international ALS specialist survey.

Heiman-Patterson TD, Cudkowicz ME, De Carvalho M, Genge A, Hardiman O, Jackson CE, Lechtzin N, Mitsumoto H, Silani V, Andrews JA, Chen D, Kulke S, Rudnicki SA, van den Berg LH.

Amyotroph Lateral Scler Frontotemporal Degener. 2018 Aug;19(5-6):331-341. doi: 10.1080/21678421.2018.1457058. Epub 2018 Apr 16.

PMID:
29661084
3.

Association Between Decline in Slow Vital Capacity and Respiratory Insufficiency, Use of Assisted Ventilation, Tracheostomy, or Death in Patients With Amyotrophic Lateral Sclerosis.

Andrews JA, Meng L, Kulke SF, Rudnicki SA, Wolff AA, Bozik ME, Malik FI, Shefner JM.

JAMA Neurol. 2018 Jan 1;75(1):58-64. doi: 10.1001/jamaneurol.2017.3339.

4.

A post hoc analysis of subgroup outcomes and creatinine in the phase III clinical trial (EMPOWER) of dexpramipexole in ALS.

Bozik ME, Mitsumoto H, Brooks BR, Rudnicki SA, Moore DH, Zhang B, Ludolph A, Cudkowicz ME, van den Berg LH, Mather J, Petzinger T Jr, Archibald D.

Amyotroph Lateral Scler Frontotemporal Degener. 2014 Sep;15(5-6):406-13. doi: 10.3109/21678421.2014.943672. Epub 2014 Aug 15.

PMID:
25125035
5.

Racial differences in motor neuron disease.

Gundogdu B, Al-Lahham T, Kadlubar F, Spencer H, Rudnicki SA.

Amyotroph Lateral Scler Frontotemporal Degener. 2014 Mar;15(1-2):114-8. doi: 10.3109/21678421.2013.837930. Epub 2013 Sep 25.

6.

Clinical variability and female penetrance in X-linked familial FTD/ALS caused by a P506S mutation in UBQLN2.

Vengoechea J, David MP, Yaghi SR, Carpenter L, Rudnicki SA.

Amyotroph Lateral Scler Frontotemporal Degener. 2013 Dec;14(7-8):615-9. doi: 10.3109/21678421.2013.824001. Epub 2013 Aug 14.

PMID:
23944734
7.

Survey of current enteral nutrition practices in treatment of amyotrophic lateral sclerosis.

Zhang M, Hubbard J, Rudnicki SA, Johansen CS, Dalton K, Heiman-Patterson T, Forshew DA, Wills AM.

ESPEN J. 2013 Feb 1;8(1):e25-e28.

8.

Dexpramipexole effects on functional decline and survival in subjects with amyotrophic lateral sclerosis in a Phase II study: subgroup analysis of demographic and clinical characteristics.

Rudnicki SA, Berry JD, Ingersoll E, Archibald D, Cudkowicz ME, Kerr DA, Dong Y.

Amyotroph Lateral Scler Frontotemporal Degener. 2013 Jan;14(1):44-51. doi: 10.3109/17482968.2012.723723. Epub 2012 Sep 17.

PMID:
22985432
9.

ALS and Frontotemporal Dysfunction: A Review.

Achi EY, Rudnicki SA.

Neurol Res Int. 2012;2012:806306. doi: 10.1155/2012/806306. Epub 2012 Aug 7.

10.

A rapidly progressing Pancoast syndrome due to pulmonary mucormycosis: a case report.

Bansal M, Martin SR, Rudnicki SA, Hiatt KM, Mireles-Cabodevila E.

J Med Case Rep. 2011 Aug 17;5:388. doi: 10.1186/1752-1947-5-388.

11.

Prevention and treatment of peripheral neuropathy after bariatric surgery.

Rudnicki SA.

Curr Treat Options Neurol. 2010 Jan;12(1):29-36. doi: 10.1007/s11940-009-0052-2.

PMID:
20842487
12.

Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III.

Kaufmann P, Thompson JL, Levy G, Buchsbaum R, Shefner J, Krivickas LS, Katz J, Rollins Y, Barohn RJ, Jackson CE, Tiryaki E, Lomen-Hoerth C, Armon C, Tandan R, Rudnicki SA, Rezania K, Sufit R, Pestronk A, Novella SP, Heiman-Patterson T, Kasarskis EJ, Pioro EP, Montes J, Arbing R, Vecchio D, Barsdorf A, Mitsumoto H, Levin B; QALS Study Group.

Ann Neurol. 2009 Aug;66(2):235-44. doi: 10.1002/ana.21743.

13.

Lambert-Eaton myasthenic syndrome following varenicline (Chantix) use.

Abou-Zeid E, Rudnicki SA, Keyrouz SG.

Muscle Nerve. 2009 Sep;40(3):486-7. doi: 10.1002/mus.21356. No abstract available.

PMID:
19697331
14.

Neuromuscular involvement in nephrogenic systemic fibrosis.

Keyrouz S, Rudnicki SA.

J Clin Neuromuscul Dis. 2007 Dec;9(2):297-302.

PMID:
18090682
15.

The importance of a respiratory therapist in the ALS clinic.

Kareus SA, Kagebein S, Rudnicki SA.

Amyotroph Lateral Scler. 2008 Jun;9(3):173-6.

PMID:
17924238
16.

Lambert-Eaton myasthenic syndrome with pure ocular weakness.

Rudnicki SA.

Neurology. 2007 May 22;68(21):1863-4. No abstract available.

PMID:
17515551
17.

Neurologic complications of gastric bypass surgery for morbid obesity.

Juhasz-Pocsine K, Rudnicki SA, Archer RL, Harik SI.

Neurology. 2007 May 22;68(21):1843-50.

PMID:
17515548
18.

Motor neuron disease in methamphetamine abusers.

Rudnicki SA, Archer RL, Labib BT.

Amyotroph Lateral Scler. 2007 Apr;8(2):126-7. No abstract available.

PMID:
17453645
19.

Survey of training programs' means for promoting neurology and attracting trainees.

Adair JC, Rudnicki SA, Boudreau E, Weiner WJ, Coyle PK, Corboy JR.

Neurology. 2006 Sep 26;67(6):936-9.

PMID:
17000957
20.

Paraneoplastic syndromes of the peripheral nerves.

Rudnicki SA, Dalmau J.

Curr Opin Neurol. 2005 Oct;18(5):598-603. Review.

PMID:
16155447
21.

Paraneoplastic syndromes of the spinal cord, nerve, and muscle.

Rudnicki SA, Dalmau J.

Muscle Nerve. 2000 Dec;23(12):1800-18. Review.

PMID:
11102903
22.

Estrogen replacement therapy in women with amyotrophic lateral sclerosis.

Rudnicki SA.

J Neurol Sci. 1999 Oct 31;169(1-2):126-7.

PMID:
10540020
23.

Nervous system dysfunction in Waldenström's macroglobulinemia: response to treatment.

Rudnicki SA, Harik SI, Dhodapkar M, Barlogie B, Eidelberg D.

Neurology. 1998 Oct;51(4):1210-3.

PMID:
9781565
24.

Factors influencing a patient's decision regarding riluzole: an early experience.

Rudnicki SA.

J Neurol Sci. 1997 Oct;152 Suppl 1:S80-1.

PMID:
9419060
25.

Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. The North America ALS/IGF-I Study Group.

Lai EC, Felice KJ, Festoff BW, Gawel MJ, Gelinas DF, Kratz R, Murphy MF, Natter HM, Norris FH, Rudnicki SA.

Neurology. 1997 Dec;49(6):1621-30.

PMID:
9409357

Supplemental Content

Loading ...
Support Center